|
Funding Agency: National Institutes of Health Title: Tobacco Regulatory Science (R01 Clinical Trial Optional) Application Deadline: Multiple deadlines The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this NOFO are expected to generate findings and data that are directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Funding Agency: National Institutes of Health Title: Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional) Application Deadline: September 26, 2023 This funding opportunity announcement (FOA) supports the development of PET radioligands that identify proteinopathies or pathological processes associated with the human biology of Alzheimer's disease related dementias (ADRDs). Activities supported under this FOA include, but are not limited to the in vitro screening of existing ligands against human ADRD brain tissue, medicinal chemistry support for development of new compounds and improvement of existing ligand specificity and selectivity, initial screening of ligands in appropriate animal models, and radioligand formulation and first-in-human testing. The Center without Walls should encompass research that will move promising ligands through in vitro and in vivo optimization to first-in-human studies. Applications must include an administrative core, a medicinal chemistry core, a clinical core, a scientific governance structure, and a minimum of two research projects with milestone plans that address workflows for screening of existing and newly derived ligands against human ADRD tissue and appropriate animal models. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease. Funding Agency: National Institutes of Health Title: NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Clinical Trial Not Allowed) Application Deadline: Multiple deadlines This Notice of Funding Opportunity (NOFO) aims to support the establishment of programs to enhance research rigor and transparency practices within academic and research institutions to promote a culture of high-quality neuroscience research. Attention to principles of rigorous study design and transparent reporting are essential to enable the neuroscientific community, as well as the biomedical community at large, to design and perform valid experiments and to assess the value of scientific findings. Awards are intended to support the implementation of innovative programs, strategies, and approaches at the departmental, inter-departmental, or equivalent intra-institutional entity level. Funding Agency: National Institutes of Health Title: Emergency Award: Novel Insights through Cross-Site Analyses of Existing RADx-UP Data (R21 Clinical Trial Not Allowed) Application Deadline: July 03, 2023 This Notice of Funding Opportunity (NOFO) will support analyses of existing RADx-UP data by proposing novel questions related to SARS-CoV-2 testing and health disparities. These projects will explore important questions focused on COVID-19 testing access and uptake, factors affecting testing and related COVID-19 outcomes, and meta-analyses of specific COVID-19 response and intervention approaches within and across populations. Funding Agency: National Institutes of Health Title: Emergency Award: RADx-UP Dissemination and Implementation (D and I) Research on COVID-19 Testing Interventions among Underserved and Vulnerable Populations (R01 Clinical Trial Optional) Application Deadline: July 10, 2023 The purpose of this Notice of Funding Opportunity (NOFO) is to support dissemination and implementation (D and I) research focused on increasing access to and uptake of coronavirus disease 2019 (COVID-19) testing interventions with the goal of reducing COVID-19 disparities and promoting health equity among underserved and vulnerable populations. This NOFO will support D and I research on how evidence-based practices, interventions, and policies are effectively translated to and used in real-world settings. Projects may evaluate the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, or seek to understand the de-implementation of practices that are ineffective, low-value, or inequitable. Interventions developed through the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) initiative are encouraged, but not required. Funding Agency: National Institutes of Health Title: Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (R34 Clinical Trial Not Allowed) Application Deadline: November 09, 2023 This Notice of Funding Opportunity (NOFO) seeks applications of limited scope proposing a set of planning activities that will lay the groundwork for a scientific project aiming to use animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the emergence of SUD risk-relevant behaviors. This planning grant funding opportunity will support planning and development of the research framework, design, and approach; including activities that will establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for an R01or equivalent NIH research award. Funding Agency: National Institutes of Health Title: NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed) Application Deadline: September 30, 2025 The NEI Center Core Grant combines three or more Resource and/or Service Cores for a group of R01 investigators to enhance their research, consolidate resources, avoid duplication of efforts, and/or contribute to cost effectiveness by providing a service with lower costs or higher quality than could be attempted for independent projects by several individual Program Directors/Principal Investigators (PD(s)/PI(s)). Shared resources and facilities that are accessible to a group of independently funded investigators lead to greater productivity for the separate projects and can provide instrumentation and facilities that are too costly to be maintained by an individual investigator. The design and purpose of each Center Core may vary in how it serves its users. This program is designed to enhance an institution's environment and capability to conduct vision research and to facilitate collaborative studies of the visual system and its disorders and promote new research within the NEI mission and Strategic Plan. Funding Agency: National Institutes of Health Title: Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional) Application Deadline: January 26, 2024 Ethical considerations are intrinsic to the conduct of robotic and bionic device research. This Notice of Funding Opportunity (NOFO) invites applications that propose research on ethical questions associated with all stages of the design, testing, and/or implementation of bionic and robotic devices. Funding Agency: Center for Disease Control and Prevention Title: Outcomes Building Capacity to Reduce the Burden of Menthol and Other Flavored Commercial Tobacco Products in Communities that Experience Health Disparities Application Deadline: July 06, 2023 This Notice of Funding Opportunity (NOFO) seeks to build a community of practice of local, diverse community collaborators together with state tobacco control programs in order to: 1) develop and advance culturally competent commercial tobacco control policies, systems, and/or environmental interventions that reduce menthol and other flavored tobacco initiation and use among youth and increase motivation for adults to quit; 2) increase opportunities for culturally appropriate cessation support that increases the likelihood of sustained cessation for those who use menthol tobacco products, and; 3) initiate appropriate and culturally competent health communication interventions that evoke behavior change. This NOFO seeks to advance health equity through strategic partnerships, community engagement, and by addressing social determinants of health (SDOH) that contribute to menthol and other flavored tobacco product use. Funding Agency: Center for Disease Control and Prevention Title: Community-Based Approaches to Reducing Sexually Transmitted Diseases (CARS) Application Deadline: June 27, 2023 CDC proposes to allocate funds to implement Notice of Funding Opportunity (NOFO) CDC-RFA-PS23-0006, Community-Based Approaches to Reducing Sexually Transmitted Diseases. The project period will be Three years, with three12-month budget periods and an anticipated project start date of September 30, 2023. The purpose of this NOFO is to implement community engagement methods to achieve health equity, via the identification and implementation of structural strategies promoting personal health. Recipients will support healthy behaviors, facilitate community-clinical linkages to build support for interventions to prevent and reduce STD disparities, enhance and sustain partnerships, support communication strategies that promote STD program successes and leverage additional resources for STD, HIV, viral hepatitis control and prevention, and evaluate the efficacy of this intervention approach. The new FOA provides support in five focus areas: (1) implementation of community engagement methods (e.g. community-based participatory research) to achieve health equity; (2) identification and implementation of systems and environmental change strategies that (a) promote sexual health and support healthy behaviors and (b) facilitate community-clinical linkages to build support for interventions to prevent and reduce STI disparities; (3) enhancement and sustainability of partnerships; (4) support for communication strategies to promote STD program successes and leverage additional resources for STI control and prevention; and (5) evaluation of the efficacy of this approach and intervention implementation. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Innovator Award Application Deadline: September 26, 2023 The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Breakthrough Award Level 4 Application Deadline: September 26, 2023 The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Era of Hope Scholar Award Application Deadline: August 8, 2023 The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Transformative Breast Cancer Consortium Award Application Deadline: September 26, 2023 The FY23 Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach by a consortium of exceptional researchers and advocates, whose collaborative efforts will make a transformative impact in breast cancer. The transformation intended by the consortium must be in people’s lives, and not in the healthcare or research system. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Breakthrough Award Levels 1 and 2 Application Deadline: August 08, 2023 The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Funding Agency: Congressionally Directed Medical Research Program Title: Breast Cancer, Breakthrough Award Level 3 Application Deadline: September 26, 2023 The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Funding Agency: Congressionally Directed Medical Research Program Title: Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP1) Focused Program Award (FPA) BAA Application Deadline: September 28, 2023 This BAA for the FY23 TBIPHRP is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for research “not related to the development of a specific system or hardware procurement”. Research and development funded through this BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge. Funding Agency: Congressionally Directed Medical Research Program Title: Traumatic Brain Injury and Psychological Health (TBIPHRP2), Focused Program Award (FPA) Application Deadline: September 28, 2023 This BAA for the FY23 TBIPHRP is intended to solicit extramural research and development ideas using the authority provided by United States Code, Title 10, Section 4001(10 USC 4001). This BAA is issued under the provisions of the Competition in Contracting Act of 1984 (Public Law 98-369), as implemented in Federal Acquisition Regulation (FAR) 6.102(d)(2) and 35.016 and in Department of Defense Grant and Agreement Regulations (DoDGARs) 22.315. In accordance with FAR 35.016, projects funded under this BAA must be for research “not related to the development of a specific system or hardware procurement”. Research and development funded through this BAA is intended and expected to benefit and inform both military and civilian medical practice and knowledge.
|
